NGL Fine Chem Ltd

NGL Fine Chem Ltd

₹ 2,324 -0.45%
02 Jul - close price
About

Established in 1981, NGL Fine-Chem Limited manufactures human and veterinary bulk drugs, intermediates, and formulations. It primarily deals in animal healthcare products such as antiprotozoal, anthelmintics, and growth promoters [1]

Key Points

Product Portfolio FY24
Presently, Veterinary APIs are the main product of the company which account for 89% of its revenues, followed by Veterinary Formulations (5%), Human APIs (3%), and Intermediates (3%).[1] The company has 26 APIs (24 Veterinary APIs, 2 Human APIs), 4 Intermediates and 10 finished dosage forms.[2]

  • Market Cap 1,436 Cr.
  • Current Price 2,324
  • High / Low 2,824 / 1,711
  • Stock P/E 34.8
  • Book Value 425
  • Dividend Yield 0.08 %
  • ROCE 20.3 %
  • ROE 17.0 %
  • Face Value 5.00

Pros

Cons

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
72 76 78 81 84 65 68 72 75 71 80 88 100
51 52 61 69 74 63 59 62 61 61 66 74 84
Operating Profit 21 24 17 12 11 2 9 10 14 10 14 14 16
OPM % 29% 31% 22% 15% 13% 3% 14% 14% 19% 14% 17% 16% 16%
2 5 4 4 3 2 0 1 1 3 3 4 4
Interest 0 0 0 0 2 0 0 0 0 0 0 0 0
Depreciation 2 2 2 2 3 4 3 1 3 3 3 3 3
Profit before tax 21 26 19 14 9 1 6 9 12 10 14 14 16
Tax % 33% 25% 27% 26% 20% 5% 25% 28% 23% 16% 25% 30% 23%
14 19 14 10 7 1 5 6 9 9 10 10 12
EPS in Rs 22.40 30.96 22.52 16.11 11.12 0.84 7.56 10.51 15.09 13.77 16.96 16.24 19.94
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
153 152 258 318 278 339
121 130 178 249 243 285
Operating Profit 32 22 80 68 35 53
OPM % 21% 14% 31% 21% 13% 16%
4 1 8 11 6 14
Interest 3 3 2 2 2 1
Depreciation 6 8 8 10 11 12
Profit before tax 28 12 78 67 27 54
Tax % 27% 31% 27% 25% 25% 24%
20 8 57 50 20 41
EPS in Rs 32.58 13.50 91.81 80.77 33.18 66.88
Dividend Payout % 5% 13% 2% 2% 5% 3%
Compounded Sales Growth
10 Years: %
5 Years: 17%
3 Years: 10%
TTM: 22%
Compounded Profit Growth
10 Years: %
5 Years: 15%
3 Years: -10%
TTM: 102%
Stock Price CAGR
10 Years: 56%
5 Years: 34%
3 Years: 5%
1 Year: 24%
Return on Equity
10 Years: %
5 Years: 21%
3 Years: 18%
Last Year: 17%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 3 3 3 3 3 3
Reserves 89 96 151 200 219 260
27 28 16 30 32 32
23 26 36 44 32 60
Total Liabilities 142 154 207 277 287 356
61 68 64 89 88 86
CWIP 0 0 12 6 26 46
Investments 9 11 29 29 39 54
73 75 102 153 133 171
Total Assets 142 154 207 277 287 356

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
9 20 27 14 35 20
-10 -20 -25 -14 -27 -27
0 -1 -1 -1 -1 -1
Net Cash Flow -1 -0 2 -1 7 -7

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 79 63 53 74 86 97
Inventory Days 106 155 132 137 69 100
Days Payable 92 116 103 91 63 114
Cash Conversion Cycle 93 102 82 120 93 83
Working Capital Days 107 93 76 117 105 168
ROCE % 14% 54% 34% 12%

Shareholding Pattern

Numbers in percentages

Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
73.81% 73.81% 73.81% 73.81% 73.81% 73.81% 73.81% 73.53% 73.53% 73.06% 73.06% 72.74%
0.00% 0.00% 0.00% 0.01% 0.05% 0.05% 0.00% 0.00% 0.00% 0.02% 0.04% 0.10%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00%
26.19% 26.19% 26.19% 26.18% 26.14% 26.13% 26.19% 26.47% 26.46% 26.93% 26.91% 27.16%
No. of Shareholders 7,14610,83215,69517,06818,04218,50418,44018,28717,06617,62316,41015,041

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls